Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Therapeutic targets of interest include mutated molecules that predispose to pancreatic cancer such as KRAS and TP53.
|
23436799 |
2013 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Dietary Garcinol Arrests Pancreatic Cancer in p53 and K-ras Conditional Mutant Mouse Model.
|
30273070 |
2018 |
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our results demonstrate that p53 mutation is an early genetic event affecting a diversity of molecular pathways in pancreatic carcinogenesis and indicates a possibility of early diagnosis of pancreatic carcinoma by detecting a few p53-positive cells obtained from the pancreatic fluid.
|
19248224 |
2009 |
Pancreatic carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our data indicate that PRIMA-1 induces apoptosis in p53 mutant pancreatic cancer cells by promoting the re-activation of p53 and inducing proapoptotic signaling pathways, providing in vitro evidence for a potential therapeutic approach in pancreatic cancer.
|
24838627 |
2014 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The clinicopathologic implications of p53 abnormalities and their effects on the efficacy of the adjuvant chemotherapy for pancreatic cancer remain controversial.
|
12561067 |
2003 |
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This study confirms that loss of chromosomes, particularly chromosomes 17 and 18, which carry the p53 and DCC genes, are common in pancreas cancer.Chromosome 20 is also frequently lost.
|
10090407 |
1999 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the relationship between SRPK2, Numb and p53 in the development of pancreatic cancer with or without chemical agent treatment in vitro.
|
30724469 |
2019 |
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer.
|
28121262 |
2017 |
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Potential functional variants in SMC2 and TP53 in the AURORA pathway genes and risk of pancreatic cancer.
|
30794721 |
2019 |
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Therefore, simultaneous analysis of p53 and K-ras mutation is suggested to enhance the genetic diagnosis of pancreatic cancer.
|
10353750 |
1999 |
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The concomitant expression of oncogenic Kras(G12D) and mutant p53 (Trp53(R172H)) in the murine pancreas results in metastatic PDA that recapitulates the cognate features of human pancreatic cancer providing an excellent animal model to identify genes required for tumor progression.
|
22158044 |
2012 |
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Advances in the understanding of pancreas cancer biology have been made over the past decade, including the discovery of critical mutations in oncogenes (i.e., K-Ras) as well as the loss of tumor suppressor genes, such as TP53 and p16(INK4).
|
16818496 |
2006 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Hypoxia-induced feedback of HIF-1α and lncRNA-CF129 contributes to pancreatic cancer progression through stabilization of p53 protein.
|
31367258 |
2019 |
Pancreatic carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Pancreatic cancer is particularly resistant to apoptosis by antineoplastic agents, which is partly attributable to the lack of functional p53.
|
11585734 |
2001 |
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In pancreatic cancer mutations in oncogenes and tumor suppressor genes are frequently detected in p53 and K-ras.
|
8862512 |
1996 |
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Although the rate of p53 mutations in pancreatic tumours is of the same order as in other adenocarcinomas (> or = 50%), an antibody response was found in only 5/78 (6.4%) sera from patients with pancreatic cancer.
|
7947080 |
1994 |
Pancreatic carcinoma
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
Enhanced phosphorylation of p53 by microRNA-26a leading to growth inhibition of pancreatic cancer.
|
26189069 |
2015 |
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Overexpression of Gli1, MDM2 and mutant p53 contributes to the development and progression of PC, and plays an important role in predicting PC patients' prognosis.
|
24289472 |
2014 |
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Together, this study highlights the therapeutic potential of NL in mutant p53 expressing pancreatic cancer.
|
29107110 |
2018 |
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Moreover, p53 mutations were detected in 7 of 15 (46.7%) cases of PCa in which the cytologic diagnosis was negative.
|
14707724 |
2004 |
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Eight out of 30 tissues from primary pancreas cancer and 3 of 4 samples from metastases showed p53 mutations.
|
8026879 |
1994 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
RESULTS The most important biotargets for plumbagin in PC were identified as TP53, MAPK1, BCL2, and IL6.
|
31230062 |
2019 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Thus, we investigate the relationship among MSI2, Numb, MDM2, and p53 in PC <i>in vitro</i> and <i>in</i><i>vivo</i>, an association that has not been reported to our knowledge.
|
28223335 |
2017 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Concurrent loss of p53 and K-ras function may contribute to the clinical aggressiveness of pancreas cancer.
|
9219065 |
1997 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Adenovirus-mediated p53 gene transfer suppressed growth of all human pancreatic cancer cell lines in a dose-dependent manner.
|
9869513 |
1998 |